Ovarian cancer test accuracy under review in 1,000 women

NCT ID NCT07539844

Recruiting now Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FRa testing, which may help guide future treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

A.C. Camargo Cancer Center - Rua Professor Antonio Prudente /ID# 280407
RECRUITING

São Paulo, 01509-900, Brazil
Biomakers /ID# 280318
RECRUITING

Buenos Aires, 1119, Argentina
Fundacion Para La Investigacion Clinica Y Molecular Aplicada Del Cancer - Ficmac /ID# 282327
RECRUITING

Bogotá, Bogota D.C., 110111, Colombia
Hospital Italiano de Buenos Aires /ID# 280315
RECRUITING

Buenos Aires, 1181, Argentina
Instituto Alexander Fleming /ID# 281479
RECRUITING

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1426, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.